GB201002419D0 - Stable live vaccine formulations - Google Patents

Stable live vaccine formulations

Info

Publication number
GB201002419D0
GB201002419D0 GBGB1002419.8A GB201002419A GB201002419D0 GB 201002419 D0 GB201002419 D0 GB 201002419D0 GB 201002419 A GB201002419 A GB 201002419A GB 201002419 D0 GB201002419 D0 GB 201002419D0
Authority
GB
United Kingdom
Prior art keywords
live vaccine
vaccine formulations
stable live
stable
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1002419.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVA LAB Ltd
Oxford University Innovation Ltd
Original Assignee
NOVA LAB Ltd
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOVA LAB Ltd, Oxford University Innovation Ltd filed Critical NOVA LAB Ltd
Priority to GBGB1002419.8A priority Critical patent/GB201002419D0/en
Publication of GB201002419D0 publication Critical patent/GB201002419D0/en
Priority to PCT/GB2011/050277 priority patent/WO2011098837A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1002419.8A 2010-02-12 2010-02-12 Stable live vaccine formulations Ceased GB201002419D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1002419.8A GB201002419D0 (en) 2010-02-12 2010-02-12 Stable live vaccine formulations
PCT/GB2011/050277 WO2011098837A1 (en) 2010-02-12 2011-02-14 Method for the production of stable live vaccine formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1002419.8A GB201002419D0 (en) 2010-02-12 2010-02-12 Stable live vaccine formulations

Publications (1)

Publication Number Publication Date
GB201002419D0 true GB201002419D0 (en) 2010-03-31

Family

ID=42110642

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1002419.8A Ceased GB201002419D0 (en) 2010-02-12 2010-02-12 Stable live vaccine formulations

Country Status (2)

Country Link
GB (1) GB201002419D0 (en)
WO (1) WO2011098837A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2498774A (en) 2012-01-27 2013-07-31 Bruce Roser Glass-stabilised biological materials and syringe
KR102141887B1 (en) 2013-01-31 2020-08-07 포틀랜드 스테이트 유니버시티 Immunogenic compositions comprising silicified virus and methods of use
PL3046536T3 (en) 2013-09-19 2019-06-28 Janssen Vaccines & Prevention B.V. Improved adenovirus formulations
US10556000B2 (en) 2014-07-18 2020-02-11 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Thermostable spray dried rotavirus vaccine formulation and process thereof
EP3359132B1 (en) * 2015-10-06 2023-08-16 Janssen Vaccines & Prevention B.V. Methods for preventing plastic-induced degradation of biologicals
MA51060A (en) * 2017-12-07 2021-03-17 Merck Sharp & Dohme DENGUE VIRUS VACCINE COMPOSITION FORMULATIONS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
GB0705245D0 (en) * 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP2254554A1 (en) * 2008-02-25 2010-12-01 Novavax, Inc. Sugar glassified virus like particles (vlps)

Also Published As

Publication number Publication date
WO2011098837A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
IL223206A0 (en) Vaccine formulations
EP2755680A4 (en) Particluate vaccine formulations
HK1179273A1 (en) Stable aqueous mia/cd-rap formulations mia/cd-rap
PL2468361T3 (en) Vildagliptin Formulations
EP2582396A4 (en) Long lasting drug formulations
GB201002419D0 (en) Stable live vaccine formulations
ZA201305986B (en) Improved insecticide formulations
ZA201300194B (en) Formulations
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
ZA201300196B (en) Formulations
GB201018645D0 (en) Formulations
GB201018649D0 (en) Formulations
GB201018648D0 (en) Formulations
GB201018647D0 (en) Formulations
GB201012589D0 (en) Formulations
GB201010494D0 (en) Formulations
GB201008470D0 (en) Formulations
GB201008358D0 (en) Formulations
GB201007959D0 (en) Formulations
GB201007702D0 (en) Formulations
GB201005587D0 (en) Novel formulations
GB201012047D0 (en) Pharmaceutical formulations
GB201012046D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)